Home›Companies›Biotech & Pharma›Persista Bio

Persista Bio Inc.

Develops an implantable cell therapy system for people with Type 1 diabetes.

Updated Nov 10, 2026·Latest SEC filing Apr 29, 2026·Suggest an edit

About Persista Bio

Persista Bio is a private company based in City of Lewes, Delaware, incorporated in 2023 in Delaware. It has reported $0 raised in one offering on Form D since April 2026. Its chief executive is Linda Tempelman.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Apr 14, 2026Apr 29, 2026$0target not set0—EquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Persista Bio's Form D filed Apr 29, 2026.

Linda Tempelman
Linda Tempelman
CEO, Cofounder and director
Also an executive officer and director at HydroSpire.

Sources

  1. SECPERSISTA BIO INC. filing history
  2. CompanyPersista Bio team
  3. CompanyNIH grants announcement